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Abstract Transforming growth factor-L (TGF-L) superfamily
members constitute a group of multifunctional factors that are
able to stimulate apoptotic cell death in a variety of cells. In this
report, we show that a zinc-finger transcription factor (TIEG) is
an immediate early gene transcriptionally induced by TGF-L in
the epithelial Mv1Lu cell line. We also demonstrate that,
mimicking TGF-L effects, ectopic overexpression of TIEG is
sufficient to trigger the apoptotic cell program in these cells,
which is preceded by a decrease of Bcl-2 protein levels. Finally,
apoptotic events elicited by TIEG overexpression can be
effectively prevented by ectopic co-expression of Bcl-2. On the
basis of these results we suggest that induction of TIEG
expression has a role in the pro-apoptotic properties of TGF-L.
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1. Introduction
Several lines of evidence indicate that apoptosis, or pro-
grammed cell death, plays an essential role during embryonic
development and later in the maintenance of homeostasis in
multicellular organisms [1,2]. In addition, when dysregulated,
its e¡ects contribute to pathogenesis of many diseases, includ-
ing cancer, autoimmunity and neurodegenerative disorders.
Apoptosis constitutes an active and gene-directed event with
a well characterized morphological and biochemical set of
cellular alterations [2^4].
Among the cytokines with the ability to trigger the onset of
apoptosis there are several transforming growth factor-L
(TGF-L) superfamily members. TGF-L mediates induction
of apoptosis in several cell types, including hepatocytes [5],
B-cell precursors [6], endothelial and epithelial cell lines [7].
Bone morphogenetic protein (BMP) 2/4 signalling may also
induce apoptosis of neural crest cells (reviewed in [8]), inter-
digital regions of developing limbs [9] or the epithelial enamel
knot during tooth formation [10].
Members of the TGF-L superfamily interact with two types
of related transmembrane serine/threonine kinase receptors.
Downstream signalling from receptor to the nucleus appears
to be mediated by the family of Smad transcriptional activa-
tors (reviewed in [11,12]). Consistent with this function, DNA
binding and transcriptional activity of various Smads have
been shown [11,12]. In addition, interaction of Smads with
additional DNA binding partners, such as FAST, AP-1 or
vitamin D receptor, are required for e⁄cient transcriptional
activation of certain target genes [13].
Although the molecular mechanisms involved in TGF-L
signalling are beginning to emerge, the mechanisms leading
to the onset of apoptosis in response to this cytokine are still
poorly understood. In this respect, recent evidence suggests
that induction of the homeobox-gene Msx-2 by BMP4 medi-
ates cell death during limb and neural crest development [14]
and that induction of a zinc-¢nger transcription factor (TIEG)
by TGF-L mediates exocrine pancreatic apoptosis [15]. TIEG
was ¢rst identi¢ed as a TGF-L inducible gene in human os-
teoblasts [16]. In addition, EGR-K, which corresponds to a
putative alternative spliced version of TIEG lacking the ¢rst
12 amino acids, was shown to have cell-cycle regulated ex-
pression in prostate cells [17]. Close homologs, named
mGIF and TIEG2 (with 85% and 91% amino acid homology
to TIEG, respectively), have recently been cloned de¢ning a
new expanding subfamily of Sp1-like transcription factors in-
volved in growth regulation [15,18]. TIEG family members are
widely expressed during development in several tissues, in-
cluding brain, bone and di¡erentiating mesenchyme, skin
and kidney [18].
In this report, we have characterized the regulation of
TIEG expression by TGF-L in epithelial cells. TIEG is tran-
scriptionally induced by TGF-L without requirement of pro-
tein synthesis. Furthermore, ectopic overexpression of TIEG
is su⁄cient to induce apoptotic cell death in Mv1Lu cells.
2. Materials and methods
2.1. TIEG cDNA, plasmids, cell lines and transfections
A cDNA encoding the full coding sequence of TIEG described in
[16] was ampli¢ed by PCR from a mouse brain cDNA library using
oligonucleotides corresponding to its amino and carboxy terminus
and analyzed by automatic sequencing. TIEGHA construct containing
the hemagglutinin (HA) epitope at the amino terminus was generated
by PCR and subcloned into a pCDNA3 vector (Invitrogen) for mam-
malian expression. The pEGFP vector encoding the green £uorescence
protein (GFP) was purchased from Clontech. COS-1, Mv1Lu and
R1B/L17 cell lines were cultured and transiently transfected with the
indicated vectors as described in [19].
2.2. GFP/Hoechst staining
Transfected cells were ¢xed in PBS containing 4% paraformalde-
hyde, stained with 4 Wg/ml Hoechst 33342 and mounted. Green £uo-
rescent protein and stained nuclei were visualized under a £uorescence
microscope.
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2.3. Analysis of DNA fragmentation
Cells were washed in PBS, lysed with 400 Wl of 10 mM Tris pH 7.4,
1 mM EDTA, 0.2% Triton X-100 and centrifuged. Cleared superna-
tants were collected and incubated at 37‡C in a lysis bu¡er containing
150 mM NaCl, 10 mM Tris-HCl pH 8, 40 mM EDTA, 1% SDS and
200 Wg/ml of proteinase K during 6^12 h. After two extractions of
phenol/chloroform/isoamyl alcohol (25:24:1), DNA was precipitated
and washed with 70% ethanol. Resuspended DNA was treated with
25^50 mg/ml of RNase A at 37‡C for 1 h. DNA was separated in 2%
agarose gel and stained with ethidium bromide.
2.4. Western analysis
Equal amounts of protein were loaded onto 10% SDS-PAGE gel
and transferred to a nitrocellulose membrane. Detection was per-
formed using a mouse monoclonal antibody against Bcl-2 (Dako)
and HA (Babco), followed by a horseradish peroxidase-conjugated
anti-mouse antibody from sheep (Amersham) and enhanced chemilu-
minescence detection (Amersham). Blots were normalized using a
monoclonal anti K-tubulin antibody (Calbiochem).
2.5. Cell viability assay
Cells were transiently transfected with the indicated plasmids to-
gether with a plasmid containing the L-galactosidase gene. The cells
that showed positive blue staining were counted under a microscope
every day after transfection and compared to their relative controls.
2.6. RNA preparation and Northern blots
Total RNA was extracted from Mv1Lu cells according to the
Chomczynski method. Northern analysis was done as described in
[20].
3. Results
Regulation of TIEG mRNA expression by TGF-L was an-
alyzed in the epithelial cell line Mv1Lu, which is highly re-
sponsive for TGF-L [21,22]. RNAs from Mv1Lu cells treated
with 1 nM TGF-L were analyzed by Northern blotting. In-
duction of TIEG mRNA was detected as early as 30 min after
the addition of TGF-L, reached maximal levels after 30^60
min, and decreased thereafter (Fig. 1A).
We next assessed whether induction of TIEG mRNA was
dependent on protein synthesis. Mv1Lu cells were treated with
TGF-L for 60 min together with the protein synthesis inhib-
itor cycloheximide (10 Wg/ml) or the RNA synthesis inhibitor
actinomycin D (1 Wg/ml). Northern analysis revealed a similar
induction of TIEG mRNA in the presence of cycloheximide
and a complete block of induction when actinomycin D was
added (Fig. 1B). These results indicate that TGF-L induces
TIEG by a transcriptional mechanism that does not require
protein synthesis.
Previous data showed cell-cycle regulated expression and
involvement of TIEG in the regulation of pancreatic cell
growth and apoptosis [15,17]. To pursue our examination
on the e¡ect of TIEG on cell growth, we overexpressed
Fig. 1. E¡ect of TGF-L on TIEG m RNA levels. A: Epithelial
Mv1L1 cells were treated with TGF-L (1 nM). Total RNA was ex-
tracted at di¡erent time points after cytokine addition and analyzed
by Northern analysis with the mouse TIEG cDNA probe. B:
Mv1Lu were treated for 60 min with 1 nM of TGF-L, and some
cultures also received cycloheximide (CHX) (10 Wg/ml) or actinomy-
cin D (Act D) (1 Wg/ml). Total RNA was extracted and TIEG ex-
pression was measured by Northern blot analysis.
Fig. 2. Overexpression of TIEG induces apoptosis in Mv1Lu cells.
A: R1B/L17 cells were transfected with TIEG, JunB or empty vec-
tor together with a plasmid expressing the L-galactosidase gene. The
viability of blue-stained cells were determined microscopically every
day after transfection and compared to their relative controls. Re-
sults are expressed as means þ S.E.M. B: Internucleosomal fragmen-
tation was analyzed using the DNA ladder assay. Mv1Lu cells were
treated with 1 nM TGF-L during 24^48 h. R1B/L17 cells transfected
with TIEG, JunB or empty vector were analyzed 2 days after trans-
fection.
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TIEG in a clone of Mv1Lu cells (R1B/L17). This clone lacks
TGF-L receptors and was selected for its high transfectability
(up to 80% e⁄ciency of transfection) [19]. Analysis of viability
of transfected and L-galactoside-positive cells showed that ec-
topic expression of TIEG not only blocked proliferation but
also resulted in a signi¢cant increase in cell death, compared
to vector or junB (previously reported as a TGF-L and BMP-
2 induced gene [22]) transfected cells (Fig. 2A). These results
raised the hypothesis that TIEG induces apoptotic cell death
rather than blocking cell cycle progression. To analyze this
possibility, we performed DNA fragmentation assays to de-
termine whether these cells become apoptotic. Mv1Lu cells
showed internucleosomal cleavage of DNA when analyzed
24^48 h after TGF-L (Fig. 2B). Similarly, transient overex-
pression of TIEG results in the formation of a DNA ladder
as a result of internucleosomal fragmentation, even without
the addition of TGF-L (Fig. 2B). Transfection of the vector
alone did not a¡ect apoptosis, nor the overexpression of junB
or L-galactosidase, used as controls. To con¢rm these e¡ects
at cellular level, we also analyzed the morphological apoptotic
feature of chromatin condensation. Individual transfected
cells were visualized by cotransfection of a green £uorescent
protein expression vector. DNA staining with Hoechst 33258
revealed that only TIEG-transfected cells (green cells) showed
chromatin margination (Fig. 3). This feature of apoptotic nu-
clei was absent in cells transfected with control vector.
Several lines of evidence suggest that di¡erent stimuli are
able to modulate the expression of Bcl-2 both transcription-
ally and post-transcriptionally [23]. First, we analyzed whether
TGF-L had any e¡ect on Bcl-2 levels by Western blotting.
Fig. 3. Chromatin analysis after overexpression of TIEG. R1B/L17 cells were transfected with a green £uorescent protein expression vector
alone (A and B) or together with a TIEG expression vector (C and D). 48 h after transfection cells were ¢xed and stained with Hoechst to
visualize nuclear chromatin (B and D).
Fig. 4. Overexpression of TIEG decreases Bcl-2 protein levels. A: Mv1Lu cells were incubated with 1 nM TGF-L for di¡erent times. B: R1B/
L17 cells were transfected with empty or TIEG encoding vectors. Cells were lysed and Bcl-2 levels analyzed by Western blotting. Results are
expressed as means þ S.E.M. of ¢ve separate experiments. Asterisks denote signi¢cant di¡erences (P6 0.05). C: R1B/L17 cells were transfected
with TIEG, TIEG and Bcl-2, Jun-B or empty plasmids. Cellular viability (transfected plus untransfected cells) were determined using a cell
counter every day after transfection and compared to their relative controls for 4 days.
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Bcl-2 protein levels fell to a half 6 to 8 h after TGF-L treat-
ment and recovered thereafter (Fig. 4A). This evidence togeth-
er with the fact that TIEG is a transcription factor that be-
longs to a family of Sp1-like zinc ¢nger proteins suggested a
possible relationship between TIEG and Bcl-2 expression lev-
els. To analyze this hypothesis, we overexpressed TIEG in
R1B/L17 cells. Results in Fig. 4B show that cells transfected
with TIEG had lower levels of Bcl-2 than those transfected
with the vector alone. We also measured caspase-3 activity
using a £uorogenic caspase-3 subfamily substrate. Neither
Mv1Lu cells treated with TGF-L nor R1B/L17 cells overex-
pressing TIEG showed signi¢cant di¡erences in caspase-3 ac-
tivity compared to their respective controls (data not shown).
We cannot rule out that technical limitations may be respon-
sible for the lack of caspase-3 activation or, alternatively, that
other caspases subfamilies with distinct substrate speci¢city
are involved in TGF-L induced apoptosis.
To examine whether Bcl-2 is able to interfere with apoptosis
induced by TIEG, we ectopically expressed Bcl-2 together
with TIEG in R1B/L17 cells and measured their viability
over time. Immunoblot assays showed only a small decrease
in TIEG expression levels in cells coexpressing Bcl-2 (data not
shown). As shown in Fig. 4C, there was a progressive loss of
transfected cells that is highly enhanced by overexpression of
TIEG. However, ectopic Bcl-2 coexpression provided almost
complete protection of those cells from death, for up to 4 days.
In addition, we also found that TIEG-induced apoptotic
DNA fragmentation was e¡ectively prevented by Bcl-2 coex-
pression (data not shown).
Taken together, these data show that TGF-L, in addition to
growth inhibition, is able to induce apoptosis in epithelial cells
and that overexpression of TIEG is su⁄cient to mimic this
apoptotic e¡ect of TGF-L.
4. Discussion
TGF-L and GDNF regulation of the expression of the
TIEG subfamily of transcription factors have been described
in osteoblasts and neuroblastoma cell lines [16,18]. Here, we
show that TIEG mRNA is highly induced soon after TGF-L
addition in epithelial cells (Fig. 1). Regulation of the steady-
state levels of TIEG may be due to regulation of its tran-
scription rate since addition of actinomycin D completely
blocked induction of its mRNA by TGF-L. In addition, in-
duction of TIEG was not a¡ected by the protein synthesis
inhibitor cycloheximide, suggesting that trans-acting factors
required for transcription pre-exist in the cell. The Smad fam-
ily of proteins are known transcriptional mediators of the
TGF-L superfamily signalling. The time course assays showed
that the pro¢le of TIEG mRNA induction is consistent with
the activation of Smads [24] suggesting that the Smad family
may mediate this TIEG transcriptional activation.
TGF-L and BMP-2 triggers apoptosis in a wide range of
cell types [5^10]. Interestingly, addition of cycloheximide
blocks TGF-L but not staurosporine-induced apoptosis in
hepatocyte cultures, suggesting a requirement of protein syn-
thesis in the early events induced by this cytokine [25]. In
addition, ectopic overexpression of components of both
BMP and TGF-L signal transduction and transcriptional ma-
chinery, such as Smad4 and TAK1, result in apoptotic cell
death both in vitro and in vivo [26,27]. This could also be the
case in the model presented here since ectopic overexpression
of TIEG is su⁄cient to induce cellular death with the mor-
phological and molecular features of apoptosis (Figs. 2 and
3). TIEG might therefore mediate some of the e¡ects of TGF-
L on apoptosis by acting as a transcriptional repressor/activa-
tor on promoters containing Sp1-like sites.
The results presented here suggest that both TGF-L and
TIEG-induced apoptosis are preceded by down-regulation of
Bcl-2 protein levels (Fig. 4), whereas no signi¢cant increases in
activity of the caspase-3 subfamily were detected. Decrease of
Bcl-2 levels becomes signi¢cant after 3 h of addition of TGF-
L, time which follows the peak of TIEG induction. To deter-
mine whether TGF-L and/or TIEG regulate Bcl-2 at the tran-
scriptional level, we analyzed a Bcl-2 promoter construct
coupled to luciferase reporter activity. Overexpression of
TIEG, or TGF-L addition, failed to repress the Bcl-2 pro-
moter in luciferase reporter assays (data not shown). We
thus suggest that TIEG may have translational or posttransla-
tional e¡ects on Bcl-2 expression, rather than a direct tran-
scriptional e¡ect. In this respect, Bcl-2 function has been
shown to be inactivated at posttranslational level by either
phosphorylation on serine residues or by both trypsin-like
and caspase-mediated proteolysis in the linker region
[23,28,29].
The apoptosis described herein was prevented by Bcl-2
overexpression. Bcl-2 can protect against both caspase-de-
pendent and independent apoptosis through prevention of
executioner caspase activation and/or stabilization of the mi-
tochondrial permeability transition pore [23,30,31]. Thus,
among the potential explanations for the role of Bcl-2 in
TGF-L-induced apoptosis is the prevention of both formation
of oxygen free radicals and reduction in mitochondrial mem-
brane potential. In fact, TGF-L action has been related to the
induction of cellular oxidative stress [32]. Moreover, TGF-L
induction of reactive oxygen species preceding the onset of
apoptosis has been described in hepatocytes, where radical
scavengers partially blocked these apoptotic e¡ects without
altering TGF-L growth-inhibitory properties [33]. In this con-
text, it has been described that TGF-L down-regulates expres-
sion of cytochrome P450 family members and that TIEG is
able to bind to the Sp1-like sites on promoters of cytochrome
P450 members [18,34].
In conclusion, the present study provides evidence of tran-
scriptional regulation of an Sp1-like transcription factor
(TIEG) by TGF-L in epithelial cells. Results also suggest
that ectopic overexpression of TIEG is su⁄cient both to de-
crease endogenous Bcl-2 levels and trigger the apoptotic cell
program, mimicking TGF-L e¡ects. These apoptotic events
elicited by TIEG can be prevented by co-expression of Bcl-
2. Taken together, these data suggest that induction of TIEG
has a role in the pro-apoptotic properties of TGF-L.
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